Navigation Links
Resverlogix Provides Quarterly Update
Date:4/28/2009

    Alzheimer's disease biomarker assessment to be added to the
    Phase 1b/2a trial

TSX Exchange Symbol: RVX

CALGARY, April 28 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or "Company") (TSX:RVX) is pleased to provide a corporate update on activities as well as an interim progress report for Resverlogix's lead drug, RVX-208. Currently Resverlogix is conducting a human Phase 1b/2a clinical trial for the assessment of RVX-208, a new class of drugs, for the treatment of atherosclerosis. The primary endpoints for this trial are safety and tolerability. To date, Resverlogix would also like to announce that RVX-208 has demonstrated that it is safe, tolerable and has favorable pharmacokinetics. The study is a double blinded placebo trial, thus an interim analysis will not be released until after the completion date of July 2009. As a result of the recently announced financing, completion of the third arm of the Phase 1b/2a trial has recommenced. Resverlogix is also pleased to announce that it will be adding a new assessment of a biomarker for Alzheimer's disease to the third and final arm of this clinical trial.

"The unmet medical need of treating subjects with low levels of ApoA-I, "the HDL protein", is huge. RVX-208 has received a great deal of recognition based on current data. In parallel with advancing the clinical program for RVX-208 we have also made distinct progress in delineating the unique mechanism of action by which RVX-208 increases ApoA-I production," stated Donald J. McCaffrey, President and CEO of Resverlogix. "This data will in part be communicated by Dr. Norman Wong, MD and Chief Scientific Officer of Resverlogix at the upcoming American Heart Association (AHA) conference," added McCaffrey.

Resverlogix is also pleased to announce that it will host a live teleconference on Thursday, April 30, 2009 at 10:00 am MDT. The purpose of the teleconference is to provide a year-end upd
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
2. Resverlogix is Presenting at IAS HDL Workshop
3. Resverlogix Honoured with World Economic Forum Technology Pioneer Award
4. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
5. Resverlogix Share Option Extension
6. Resverlogix Notice of Conference Call & Webcast
7. /C O R R E C T I O N from Source -- Resverlogix Corp./
8. Industry Leaders Select Resverlogixs RVX-208
9. Resverlogixs Lead Drug Featured in Key Scientific Publication
10. Jan Gray Joins Resverlogix Board of Directors
11. Resverlogix Notice of Conference Call & Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/5/2015)... ... July 06, 2015 , ... For many years, metal-on-quartz filters ... a high-end machine such as a Varian Cary 4000-7000, a Perkin Elmer 800-1100 or ... design that even NIST used them for their SRM-2031 series going back for many ...
(Date:7/3/2015)... (PRWEB) , ... July 03, 2015 , ... ... highly-regarded by Fortune 500 companies and professional service industries alike-- typically known for ... make clients laugh, honor a good cause and break from their day jobs. ...
(Date:7/3/2015)... Forskere kan søke ... Science", som finner sted i ... på  http://www.openinnovationinscience.at , og søknadsperioden varer frem ... to største utfordringene innen helsevitenskapen er mangelen ... og kompleksiteten av nåværende forskningsresultater, i følge ...
(Date:7/2/2015)... ... July 03, 2015 , ... Cuvettes have been used in countless labs for decades. ... the cuvette they needed. As expected, this was a daunting and tiring process looking ... because they were not able to navigate the complex catalog structure. , Now thanks to ...
Breaking Biology Technology:FireflySci Simplifies the Calibration of UV Spectrophotometers with FUV Photometric Accuracy Standards 2FireflySci Simplifies the Calibration of UV Spectrophotometers with FUV Photometric Accuracy Standards 3The Alexander Group Declares Their Independence with a Bit of Levity 2Lansering av verdens første Open Innovation-program for utdanning av forskere 2Lansering av verdens første Open Innovation-program for utdanning av forskere 3New Cuvette E-Commerce Website Launched by FireflySci 2
... the Cost of Genome Analysis to $100 In ... Routine Medical Care-PHILADELPHIA, Feb. 24 BioNanomatrix, Inc., ... analysis platforms for biomedical research, molecular diagnostics and ... genome analysis technology, along with founder and chief ...
... Gene Network Sciences, Inc. (GNS) today announced that it ... Officer of Stromedix, Inc. and former Executive Vice President ... Directors. Dr. Gilman has been Founder and Chief ... was previously Executive Vice President, Research at Biogen Idec. ...
... PharmAthene, Inc. (NYSE Alternext US: PIP), a biodefense ... threats, announced today that results from a Phase ... for Valortim(R) were presented at the 7th Annual ... held in Baltimore, MD, February 22-25, 2009. David ...
Cached Biology Technology:BioNanomatrix's Revolutionary Whole Genome Analysis Platform Named to MIT Technology Review's Annual 10 Emerging Technologies List 2BioNanomatrix's Revolutionary Whole Genome Analysis Platform Named to MIT Technology Review's Annual 10 Emerging Technologies List 3Gene Network Sciences Announces Michael Gilman as Board Member 2PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting 2PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting 3PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting 4PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting 5PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting 6PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting 7
(Date:6/17/2015)... Maryland , and HILDEN, Germany , ... QGEN ; Frankfurt Prime Standard: QIA) today launched new ... evidence in forensic laboratories in the United States ... solution to simultaneously analyze multiple key genomic markers (short tandem ... ® Quality Sensor to evaluate the quality of DNA ...
(Date:6/16/2015)... , June 16, 2015 Fingerprint ... touch fingerprint sensors in the company,s portfolio from one of ... are planned to mainly take place during the third quarter ... Asia . Jörgen Lantto, CEO ... of    the   growing interest from smartphone OEMs in ...
(Date:6/12/2015)... -- Securus Technologies, a leading provider of civil and ... corrections and monitoring, announced the United States Patent ... and identify participants of a video visitation session ... system can: , Identify that the ... process is actually the person participating in the ...
Breaking Biology News(10 mins):QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5FPC Receives Order for Touch Fingerprint Sensors of 375 MSEK 2Securus Announces Patent Issued for Authorized Presence Verification During Video Visitation 2
... the leading cause of blindness in western society, say experts ... a new eye instrument, they have launched a study to ... strength could also explain why the 77-year-old sailor has no ... sweetcorn, kale and broccoli are rich in a chemical called ...
... virtually any other type of therapy, has given rise ... also great concerns regarding health risks. Since the Deutsche ... in 1995, this field of research has developed enormously. ... as well as the risks of gene therapy. The ...
... to accurately distinguish benign from malignant breast lesions. ... and harmless lesions in nearly all of the ... the annual meeting of the Radiological Society of ... imaging has been found to have high specificity,?said ...
Cached Biology News:Why Popeye only has eyes for spinach 2Development of gene therapy 2Elasticity imaging identifies cancers and reduces breast biopsies 2
Collected from 8-12 week old sexually mature rats. Pricing: $100/unit for 1 - 10 units...
... strains are K-12 derivatives that have mutations ... glutathione reductase (gor) genes, which greatly enhances ... have shown that expression in Origami(DE3) yielded ... host even though overall expression levels were ...
... The GenoStat Inducible Expression System provides ... in mammalian cells and is capable of ... control is mediated by the highly specific ... chimeric bipartite nuclear receptor complex. Gene expression ...
Request Info...
Biology Products: